Bethany Verkamp, MD

Loading...

Member, Division of Bone Marrow Transplantation and Immune Deficiency
Instructor, UC Department of Pediatrics

bethany.verkamp@cchmc.org
Board Certified

Burnet Campus

Make An Appointment

Existing PatientsMyChart Scheduling

AppointmentsCall Us to ScheduleAppointments1-513-636-3200

About

Biography

I am an instructor of pediatrics and a member of the Division of Bone Marrow Transplantation and Immune Deficiency.

I earned my medical degree from the University of Arkansas for Medical Sciences in Little Rock, Arkansas, and completed both my pediatric residency and my fellowship in hematology/oncology at Cincinnati Children’s.

My clinical and research interests focus on pediatric bone marrow transplant and cellular/immunotherapies. I have specific interests in hemophagocytic lymphohistiocytosis (HLH) and other primary immune regulatory disorders, malignancy-associated immune dysregulation and understanding the mechanisms and prevention of mixed chimerism following bone marrow transplant.

Interests

Pediatrics; hematology; oncology

Services and Specialties

Location

Burnet Campus

3333 Burnet Ave
Cincinnati, OH 45229

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information

Publications

Pediatric hemophagocytic lymphohistiocytosis: current conceptualization, diagnosis, and treatment. Verkamp, B; Jordan, MB; Allen, CE. Blood. 2026; 147(10):1019-1036.

Clinical Impact of Bronchoalveolar Lavage in Pediatric and Young Adult Patients With Cancer and Suspected Respiratory Infections. Whitehurst, D; Otto, W; Verkamp, B; Paulsen, G; Danziger-Isakov, L; Miller-Handley, H. Journal of the Pediatric Infectious Diseases Society. 2025; 14(1).

Emapalumab therapy for hemophagocytic lymphohistiocytosis before reduced-intensity transplantation improves chimerism. Verkamp, B; Jodele, S; Sabulski, A; Marsh, R; Kieser, P; Jordan, MB. Blood. 2024; 144(25):2625-2636.

Early response markers predict survival after etoposide-based therapy of hemophagocytic lymphohistiocytosis. Verkamp, B; Zoref-Lorenz, A; Francisco, B; Kieser, P; Mack, J; Blackledge, T; Brik Simon, D; Yacobovich, J; Jordan, MB. Blood advances. 2023; 7(23):7258-7269.

Pupil Size and Reactivity in Pediatric Patients With Sickle Cell Disease. Mack, JM; Frankowski, S; Verkamp, B; Crary, SE; Spray, B; Crawley, L; Saccente, S; Neville, KA. Journal of Pediatric Hematology/Oncology. 2023; 45(1):e44-e47.

Early Response Parameters during Etoposide-Based Hemophagocytic Lymphohistiocytosis Treatment in Children Predict Early Mortality. Yacobovich, J; Verkamp, B; Francisco, BJ; Mack, JM; Blackledge, T; Simon, DB; Zoref-Lorenz, A; Jordan, MB. Blood. 2022; 140(Supplement 1):2612-2613.

Effect of sirolimus on coagulopathy of slow-flow vascular malformations. Mack, JM; Verkamp, B; Richter, GT; Nicholas, R; Stewart, K; Crary, SE. Pediatric Blood and Cancer. 2019; 66(10):e27896.

From the Blog

Rare Diseases

Emapalumab Extends ‘Intervention-Free’ Survival for Children with HLH

Bethany Verkamp, MD, Michael B. Jordan, MD9/4/2024

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent experience management company, Qualtrics. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey

Loading ...